- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02965924
Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes
October 2, 2019 updated by: Arthur J. Sit, M.D., Mayo Clinic
Effect of Topical Phenylephrine 2.5% on Episcleral Venous Pressure in Normal Human Eyes
Phenylephrine hydrochloride ophthalmic solution is an alpha-1 adrenergic receptor agonist commonly used topically for dilation prior to ocular fundus examination.
In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial dilator muscle of the iris.
Episcleral venous pressure (EVP) is a determinant of intraocular pressure (IOP) and can be measured non-invasively by venomanometry.
Since phenylephrine is a vasoconstrictor, it may affect episcleral venous tone, but the effect on EVP is unknown.
Understanding the physiology of episcleral veins helps us in better understanding of pathophysiology of glaucoma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Any self-declared ethno-racial category.
- Medically healthy subjects.
- Subjects with two healthy eyes.
- Intraocular pressure (IOP) less than 22 mmHg in each eye.
- Best-corrected visual acuity (BCVA) in each eye 20/50 or better.
- Open angles in both eyes.
- Contact lens wear stopped at least 3 days prior to study, and during the study.
- Ability to cooperate for examinations required for study.
Exclusion Criteria:
- Chronic or acute ophthalmic diseases including glaucoma, wet type macular degeneration, uveitis and clinically significant cataract.
- Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis.
- Cornea pathologic changes preventing reliable measurement.
- Narrow anterior chamber angle.
- Previous intraocular surgeries, laser procedures, and intravitreal injections.
- Previous corneal refractive surgeries.
- Myopia greater than -6.00 D spherical equivalent.
- Hyperopia greater than +2.00 D spherical equivalent.
- Lack of suitable episcleral vein for measurement.
- Ocular trauma within the past 6 months.
- Ocular infection or ocular inflammation in the past 3 months.
- Ocular medication of any kind within 30 days of study visit.
- Known hypersensitivity to Phenylephrine or topical anesthetic medication.
- Severe hypertension: Systolic blood pressure greater than 180 mmHg and/or diastolic blood pressure greater than 105 mmHg.
- A known history of ischemic heart disease (angina or myocardial infarction), cerebrovascular accidents, cardiac arrhythmias, cerebral or aortic aneurysms.
- Uncontrolled diabetes mellitus.
- Uncontrolled hyperthyroidism.
- Use of some systemic medications within 30 days prior to study including: β-adrenergic antagonists, α-adrenergic agonists and antagonists, calcium channel blockers, diuretics, vasodilators, monoamine oxidase inhibitors, and systemic steroids.
- Participation in any interventional study within the past 30 days prior to study visit.
- Women who are pregnant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phenylephrine
Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.
|
Instilling phenylephrine 2.5% eye drop
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Episcleral Venous Pressure (EVP)
Time Frame: baseline, 60 minutes
|
EVP will be measured non-invasively using a custom-modified slit-lamp mounted venomanometer.
This device utilizes the pressure chamber technique, in which a clear flexible balloon is placed against the conjunctival surface of the eye, and the pressure is increased until an episcleral vein is noted to blanch.
The system for pressure-chamber based venomanometry includes a computer-controlled motor drive to increase pressure automatically, a transducer to record pressure, and a high-definition video camera to record vein collapse.
Pressure measurements are synchronized with the video stream and image analysis software is used to determine the pressure required to collapse the vein to a specific pre-determined degree as measured in mmHg.
|
baseline, 60 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Intraocular Pressure (IOP)
Time Frame: baseline, 60 minutes
|
Intraocular pressure will be measured in mmHg after topical anesthesia by using the pneumatonometer.
There will be a minimum of three IOP measurements and a mean will be accepted as IOP.
|
baseline, 60 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Arthur J Sit, M.D., Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2016
Primary Completion (Actual)
October 1, 2018
Study Completion (Actual)
October 1, 2018
Study Registration Dates
First Submitted
November 15, 2016
First Submitted That Met QC Criteria
November 15, 2016
First Posted (Estimate)
November 17, 2016
Study Record Updates
Last Update Posted (Actual)
October 23, 2019
Last Update Submitted That Met QC Criteria
October 2, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Cardiotonic Agents
- Respiratory System Agents
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Nasal Decongestants
- Adrenergic alpha-1 Receptor Agonists
- Phenylephrine
- Oxymetazoline
Other Study ID Numbers
- 16-007077
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Assess Phenylephrine on EVP and IOP
-
Egalet LtdCompletedAssess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac TromethamineUnited Kingdom
-
Singapore Clinical Research InstituteSingapore General Hospital; Duke-NUS Graduate Medical SchoolTerminatedAssess the Effects of a the 90-day Oral TS Study Regimen on PSA, IPSS, Haemoglobin and Haematocrit, and to Assess Adverse and Serious Adverse Events.Singapore
-
The Touro College and University SystemUniversity of Vienna; Osato Research Institute; University of Mauritius; Mauritius... and other collaboratorsCompletedAssess the Effect of Green Tea on Diabetes | Assess the Effect of Fermented Papaya Pretration on Diabetes | Effects of Green Tea and FPP on C-reactive Proteins | Effects of Green Tea and FPP of Lipid Profiles in Diabetes | Effect of Green Tea and FPP on Atheroma FormationAustria, Mauritius, United States
-
Institut Pasteur de LilleLuxomedTerminatedAssess the Effect of an IR Reflexotherapy on Overweight and Class I Obese PeopleFrance
-
Helm Vision GroupRecruitingThe Focus of the Study is to Assess the Effectiveness of Topical Ivermectin on Eliminating Eyelash SleevesUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownTo Assess the Beneficial Preemptive and Preventive Effects of PGL on the Immediate and Late (1- and 3 Months) Postoperative Analgesia Requirements
-
International Centre for Diarrhoeal Disease Research...UnknownAssess the Impact of Moringa Leaves on Serum Heamoglobin and Vitamin A Level Among the Adolescent GirlsBangladesh
-
University of the West of ScotlandSwansea UniversityCompletedTo Assess the Impact of the HIT Intervention on Physiological Responses | To Assess the Role of a Secondary High School as a Setting for Promoting Healthy Eating and PA Behaviours | To Determine the Associations Between CVD Risk Factors at Baseline in 15 - 18 Year Old YouthUnited Kingdom
-
Seoul National University HospitalUnknownTo Assess the Feasibility of CT-derived FFR, WSS and TPF on Coronary Atherosclerotic PlaqueKorea, Republic of
-
Centre hospitalier de Ville-Evrard, FranceCompletedThe Objective of Our Study is to Assess and Take Into Account Early on the Suffering of Family MembersFrance
Clinical Trials on Phenylephrine 2.5%
-
Eyenovia Inc.Completed
-
Eyenovia Inc.Completed
-
University of the PhilippinesCompleted
-
USDA Beltsville Human Nutrition Research CenterPenn State UniversityCompletedHealthy VolunteersUnited States
-
Abiomed Inc.McGill University Health Centre/Research Institute of the McGill University...Terminated
-
Dong-A ST Co., Ltd.Not yet recruitingHealthyKorea, Republic of
-
Dong-A ST Co., Ltd.Not yet recruitingHealthyKorea, Republic of
-
Abiomed Inc.TerminatedST-elevation Myocardial Infarction
-
Galderma R&DCompleted
-
Galderma R&DCompletedAcne VulgarisUnited States, Canada